Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.
Fouquet G et al. J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Mark TM et al. Leuk Lymphoma. 2014 Mar 25. [Epub ahead of print].
Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.
Parmar SR et al. Bone Marrow Transplant. 2014 Mar 24. doi: 10.1038/bmt.2014.56. [Epub ahead of print].
Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.
Mohty M et al. Haematologica. 2014 Mar;99(3):408-16. doi: 10.3324/haematol.2013.096149.